查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571995

聚乙二醇化蛋白質的全球市場

PEGylated Proteins
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球聚乙二醇化蛋白質市場預計將達到 20 億美元

聚乙二醇化蛋白質的全球市場預計 2023 年為 11 億美元，預計到 2030 年將達到 20 億美元，2023-2030 年分析期間複合年成長率為 9.1%。聚乙二醇化蛋白質消耗品是本報告分析的細分市場之一，預計複合年成長率為 8.5%，到分析期結束時將達到 13 億美元。分析期間，聚乙二醇化蛋白質服務產業的複合年成長率預計為 10.5%。

美國市場預估為2.949億美元，中國預期複合年成長率為8.5%

預計 2023 年美國聚乙二醇化蛋白市場規模將達 2.949 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達3.063億美元，2023-2030年分析期間複合年成長率為8.5%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 7.8% 和 8.0%。在歐洲，德國預計複合年成長率為 7.2%。

全球聚乙二醇化蛋白質市場—主要趨勢與促進因素總結

科技進步如何推動聚乙二醇化蛋白質的發展？

聚乙二醇化蛋白質將聚乙二醇 (PEG) 鏈附著在蛋白質上，由於其能夠改善生技藥品的藥物動力學和治療功效，因此在生物製藥開發中變得越來越重要。蛋白質工程和聚乙二醇化技術的進步使得蛋白質的修飾變得更加精確和可控，從而提高了治療性蛋白質的穩定性、降低了免疫抗原性並增加了溶解度。這些創新使聚乙二醇化蛋白質能夠在血液中循環更長時間，從而減少給藥頻率並提高患者的依從性。最近的趨勢包括位點特異性聚乙二醇化技術的創建。這確保了 PEG 分子指定在蛋白質上並保持蛋白質的生物活性。此外，聚乙二醇化化學的進步提高了聚乙二醇化酶、勝胜肽和抗體的功效，使它們在腫瘤學、免疫學和血液學等各種治療領域中具有更廣泛的用途。這些突破不僅推動了藥物開發，也改善了接受生技藥品治療的患者的治療結果。

為什麼生物製藥對聚乙二醇化蛋白質的需求量很大？

生物製藥領域對聚乙二醇化蛋白質的需求正在迅速增加，這主要是因為它們能夠克服與基於蛋白質的治療相關的許多挑戰。聚乙二醇化的主要優點之一是它能夠降低蛋白質的免疫抗原性，使它們不太可能被免疫系統識別和破壞。這項特性在生物製藥開發中特別有價值，因為它提高了蛋白質療法的安全性和有效性。聚乙二醇化蛋白質也更能抵抗體內酵素的分解，且半衰期顯著更長，這可以減少給藥頻率並提高患者的依從性。這對於需要長期治療的慢性疾病尤其有益。此外，聚乙二醇化蛋白質在標靶藥物傳遞方面也顯示出巨大的潛力，可以將治療性蛋白質精確地遞送到特定的組織和細胞，同時最大限度地減少脫靶效應。隨著對長效、有效和患者友好的生技藥品的需求不斷成長，聚乙二醇化蛋白質正在成為下一代治療的重要組成部分。

醫療保健和監管標準的變化如何影響聚乙二醇化蛋白質市場？

醫療保健領域不斷變化的趨勢，特別是對個人化醫療和標靶治療的日益重視，對聚乙二醇化蛋白質的採用產生了重大影響。隨著生物製藥成為主流治療藥物，對更安全、更有效且針對個別患者需求的治療的需求不斷成長。聚乙二醇化蛋白質符合個人化醫療的原則，具有可客製化的藥物動力學和減少的副作用。此外，監管環境在塑造聚乙二醇化蛋白質市場方面發揮重要作用。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構專注於核准證明臨床療效又能降低免疫抗原性風險的生技藥品，而聚乙二醇化這使其成為對開發商有吸引力的策略。生物相似藥尤其是聚乙二醇化生物相似藥的需求也在上升，為市場拓展提供了新的機會。隨著醫療保健系統越來越重視基於價值的醫學，聚乙二醇化蛋白質提供了一種創新的解決方案，可以滿足對安全、有效和長效生技藥品的需求。

推動聚乙二醇化蛋白質市場成長的因素有哪些？

聚乙二醇化蛋白質市場的成長受到多種因素的推動，例如技術進步、對生技藥品的需求不斷增加以及轉向以患者為中心的護理模式的轉變。主要促進因素之一是癌症、自體免疫疾病和糖尿病等慢性疾病的盛行率不斷上升，這些疾病需要長期使用蛋白質為基礎的療法進行治療。聚乙二醇化蛋白質可延長半衰期並提高療效，減少頻繁給藥的需要並提高患者的依從性。位點特異性聚乙二醇化和控制釋放機制的技術進步也正在推動市場發展，以實現更精確的治療結果。此外，生物製藥產業對生物相似藥開發的日益關注也推動了對聚乙二醇化蛋白質的需求。對生技藥品和生物相似藥開發的監管支持，加上醫療保健支出的增加，正在進一步推動市場成長。隨著醫療保健提供者和製藥公司尋求開發更有效和對患者友好的治療方法，聚乙二醇化蛋白質有望在推進生物製藥療法方面發揮關鍵作用。

受訪企業範例（共46家）

  • BIA Separations doo
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP13899

Global PEGylated Proteins Market to Reach US$2.0 Billion by 2030

The global market for PEGylated Proteins estimated at US$1.1 Billion in the year 2023, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2023-2030. PEGylated Protein Consumables, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the PEGylated Protein Services segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$294.9 Million While China is Forecast to Grow at 8.5% CAGR

The PEGylated Proteins market in the U.S. is estimated at US$294.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global PEGylated Proteins Market – Key Trends & Drivers Summarized

How Are Technological Advancements Enhancing the Development of PEGylated Proteins?

PEGylated proteins, which involve the attachment of polyethylene glycol (PEG) chains to proteins, have become increasingly important in biopharmaceutical development due to their ability to improve the pharmacokinetics and therapeutic efficacy of biologics. Advances in protein engineering and PEGylation technologies are enabling more precise and controlled modification of proteins, leading to improved stability, reduced immunogenicity, and enhanced solubility of therapeutic proteins. These technological innovations allow PEGylated proteins to have prolonged circulation times in the bloodstream, thereby reducing the frequency of dosing and improving patient compliance. Recent developments also include the creation of site-specific PEGylation techniques, which ensure that the PEG molecule attaches to a predetermined location on the protein, preserving the protein’s biological activity. Additionally, advances in PEGylation chemistry are improving the efficacy of PEGylated enzymes, peptides, and antibodies, making them more versatile and applicable across various therapeutic areas, including oncology, immunology, and hematology. These breakthroughs are not only advancing drug development but are also improving the therapeutic outcomes for patients undergoing treatment with biologics.

Why Are PEGylated Proteins in High Demand Across Biopharmaceuticals?

The demand for PEGylated proteins is rapidly increasing within the biopharmaceutical sector, primarily due to their ability to overcome many of the challenges associated with protein-based therapeutics. One of the key benefits of PEGylation is its ability to reduce the immunogenicity of proteins, making them less likely to be recognized and destroyed by the immune system. This property is particularly valuable in the development of biopharmaceuticals, as it enhances the safety and efficacy of protein therapeutics. PEGylated proteins are also more resistant to degradation by enzymes in the body, which significantly extends their half-life, allowing for reduced dosing frequencies and improved patient adherence. This is especially beneficial for chronic conditions that require long-term treatment. Furthermore, PEGylated proteins have shown considerable promise in targeted drug delivery, enabling precise delivery of therapeutic proteins to specific tissues or cells while minimizing off-target effects. As the demand for long-acting, effective, and patient-friendly biologics continues to grow, PEGylated proteins are emerging as a key component of next-generation therapies.

How Are Shifts in Healthcare and Regulatory Standards Impacting the PEGylated Proteins Market?

Shifting trends in healthcare, particularly the growing emphasis on personalized medicine and targeted therapies, are significantly influencing the adoption of PEGylated proteins. With the rise of biologics as a leading class of therapeutics, there is increasing demand for treatments that can be tailored to individual patient needs while offering enhanced safety and efficacy. PEGylated proteins, with their customizable pharmacokinetics and reduced side-effect profiles, align well with the principles of personalized medicine. Additionally, the regulatory landscape is playing a crucial role in shaping the PEGylated proteins market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are focusing on approving biologics that demonstrate both clinical efficacy and reduced immunogenic risks, making PEGylation an attractive strategy for drug developers. The demand for biosimilars, particularly PEGylated biosimilars, is also on the rise, providing new opportunities for market expansion. As healthcare systems increasingly prioritize value-based care, PEGylated proteins offer an innovative solution that aligns with the need for safe, effective, and long-acting biologics.

What Factors Are Driving Growth in the PEGylated Proteins Market?

The growth in the PEGylated proteins market is driven by several factors, including technological advancements, rising demand for biologics, and the shift toward patient-centric care models. One of the primary drivers is the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes, which require long-term treatment with protein-based therapies. PEGylated proteins offer extended half-lives and improved efficacy, reducing the need for frequent dosing and improving patient adherence. Technological advancements in site-specific PEGylation and controlled-release mechanisms are also propelling the market, enabling more precise therapeutic outcomes. Additionally, the biopharmaceutical industry's growing focus on developing biosimilars is driving demand for PEGylated proteins, as they offer a cost-effective alternative to branded biologics with comparable efficacy. Regulatory support for the development of biologics and biosimilars, coupled with increasing healthcare spending, is further boosting market growth. As healthcare providers and pharmaceutical companies seek to develop more effective and patient-friendly treatments, PEGylated proteins are poised to play a critical role in advancing biologic therapies.

Select Competitors (Total 46 Featured) -

  • BIA Separations d.o.o.
  • Biomatrik Inc.
  • Celares GmbH
  • Creative PEGWorks
  • IRIS Biotech GmbH
  • Jenkem Technology Co., Ltd.
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • PEGylated Proteins - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Biopharmaceuticals Drives Growth in the PEGylated Proteins Market
    • Technological Advancements in PEGylation Processes Enhance the Stability and Efficacy of Biologic Drugs
    • Increasing Use of PEGylated Proteins in Cancer Treatment Expands Opportunities in Oncology
    • Growing Adoption of PEGylated Therapeutics in Rare Disease Treatment Strengthens Market Growth
    • Rising Focus on Prolonging Drug Half-Life Drives Demand for PEGylated Proteins in Drug Delivery Systems
    • Advancements in Site-Specific PEGylation Techniques Enhance Precision and Effectiveness of Therapeutics
    • Growing Applications of PEGylated Proteins in Immunotherapy and Vaccines Expands Market Potential
    • Increased Use of PEGylated Enzymes in Metabolic Disorders Expands Opportunities in Enzyme Replacement Therapy
    • Rising Research and Development in Biotechnology Fuels Innovation in PEGylated Protein Therapeutics
    • Technological Integration of PEGylation with Monoclonal Antibodies Enhances Targeted Drug Delivery
    • Increasing Adoption of PEGylated Proteins in Chronic Disease Management Strengthens the Case for Long-Term Therapeutics
    • Growing Use of PEGylated Liposomes in Drug Formulations Expands Market for Advanced Drug Delivery Systems
    • Rising Focus on Reducing Immunogenicity in Protein Therapeutics Drives Growth in PEGylation Technologies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PEGylated Proteins Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 25: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: USA 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: USA 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Canada 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Canada 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • JAPAN
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Japan 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Japan 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • CHINA
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: China 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: China 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • EUROPE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • FRANCE
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: France 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: France 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • GERMANY
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Germany 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Germany 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Italy 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Italy 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • UNITED KINGDOM
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: UK 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UK 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • ASIA-PACIFIC
    • PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 95: Rest of World 7-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2024 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 97: Rest of World 7-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World 7-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2024 & 2030

IV. COMPETITION